Published in final edited form as:

J Cell Biochem. 2015 January ; 116(1): 115–123. doi:10.1002/jcb.24948.

The Presence of Androgen Receptor Elements Regulates ZEB1 Expression in the Absence of Androgen Receptor

Steven M. Mooney^{5,*}, Princy Parsana^{5,10}, James R. Hernandez⁵, Xin Liu^{1,2,4}, James E. Verdone⁵, Gonzalo Torga⁵, Calvin A. Harberg^{3,5}, and Kenneth J. Pienta^{5,6,7,8,9}

¹Department of Chemistry, Fudan University, Shanghai 200433, China

²Institute of Biomedical Sciences, Fudan University, Shanghai 200032, China

³Department of Surgery, University of Wisconsin School of Medicine and Public Health, Division of Transplantation, Madison, Wisconsin

⁴Department of Biological Chemistry, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287

⁵The James Buchanan Brady Urological Institute and Department of Urology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287

⁶Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287

⁷Department of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287

⁸Department of Chemical and Biomolecular Engineering, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287

⁹Department of Cellular and Molecular Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287

¹⁰Department of Computer Science, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287

Abstract

Zinc finger E-box binding homeobox 1 (ZEB1) is a transcription factor that plays a central role in the epithelial to mesenchymal transition (EMT) of cancer cell lines. Studies on its regulation have mostly focused on the negative 3'UTR binding of miR200c. Interestingly, it has been previously reported that androgen receptor (AR) regulates ZEB1 expression in breast and prostate cancers. In order to validate this, various ZEB1 promoter deletions were cloned into a luciferase reporter system to elucidate the contribution of two putative androgen response elements (AREs). The in vivo contribution of AR was also assessed in cell lines after R1881 treatment using qPCR with

*Correspondence to: Steven M. Mooney, The James Buchanan Brady Urological Institute and Department of Urology, The Johns Hopkins University School of Medicine, Baltimore, MD 21287. smooney4@jhmi.edu.
Steven M. Mooney, Princy Parsana, James R. Hernandez, and Xin Liu contributed equally to this work.

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of this article at the publisher's web-site.

prostate specific antigen (PSA) as the positive control. We discovered that AR upregulates the levels of expression of ZEB1 10-fold on a luciferase promoter that only contains the distal ARE. However, when the proximal ARE is included, no additional activation is apparent with AR or its hormone independent variant, AR-V7. Furthermore, we demonstrate here that a promoter construct containing both AREs activates transcription of ZEB1 even in the AR-null cell lines DU145 and PC3. Incubation of the AR-positive cell line, LNCaP with R1881, failed to substantially increase the expression levels of ZEB1. Despite the presence of AREs in the promoter region, it appears that ZEB1 expression can be induced even without AR. In addition, the region around the distal ARE is a potent repressor in AR-null cell lines.

Keywords

androgen receptor (AR); ZEB1/TCF8; prostate cancer; OVOL1; OVOL2; epithelial to mesenchymal transition (EMT); luciferase assays

ZEB1 is a zinc finger transcription factor that can be overexpressed in various cell lines to induce EMT by suppressing E-cadherin (CDH1) and MYB [Moes et al., 2012; Hugo et al., 2013]. ZEB1 is also indirectly able to induce stem cell factors through repression of miR200 family members which themselves repress stemness factors including Sox2 and Klf4 [Wellner et al., 2009].

Induction of ZEB1 protein has been shown in response to long-term exposure to chemotherapy [Kim et al., 2013], incubation with M2 macrophages [Roca et al., 2013] and hypoxia [Salnikov et al., 2012] highlighting the importance of the tumor microenvironment [Yang et al., 2014]. The exact sequence of events that leads environmental stress to increase ZEB1 expression remains unknown. Interestingly, downregulation of ZEB1 is generally thought to be mediated at the mRNA level by miR200c, thus causing a negative feedback in which miR200c represses ZEB1 and vice-versa [Moes et al., 2012]. However, little has been done to determine which factors positively regulate ZEB1 expression.

One of the most common treatments for PCa is chemical castration which inhibits the positive feedback of androgens within the cancer cells. Although androgen deprivation is the “gold standard” of therapy, it has been suggested that therapy induces or causes a positive selection for aggressive, androgen-independent cancer cells [Sun et al., 2012]. Castration also reduces the levels of circulating androgens, which is the ligand that binds to AR and allows it to localize to the nucleus [Ni et al., 2013]. While prostate cancer is initially dependent on androgen in the early stages of the disease, it rapidly becomes androgen-insensitive if the patient is treated with anti-androgens [Hu et al., 2009]. Several known mechanisms in which this malady can become androgen-insensitive are: (1) AR can be overexpressed to levels that allow it to become even more sensitive to even low levels of circulating androgen or androgen-like hormones; (2) splice variants that lack the ligand binding domain can be produced which localize to the nucleus in the absence of hormones; (3) phosphorylation of the ligand binding domain; and (4) prostate cancer can simply down-regulate AR in favor of other methods of growth [Pienta and Bradley, 2006]. The use of anti-androgens may even lead prostate cancer to become more aggressive through EMT [Sun et al., 2012]. This report investigates how AR may potentially contribute to EMT by

modulating ZEB1 expression, a master regulator that can independently lead to an EMT in prostate cancer models.

MATERIALS AND METHODS

DNA EXPRESSION PLASMID CONSTRUCTS

AR-V7 and AR-FL were cloned into the pcDNA3.1 vector. GFP-AR and GFP-ARV7 were cloned into GFP-C1 [Hu et al., 2012]. All ZEB1-luciferase constructs used were in pGL4 (Promega) and pGL4-ZEB1_{-867/-66} was specifically obtained from Dr. Carole Mendelson of UT Southwestern [Renthall et al., 2010].

CELL CULTURE

DU145-TxR and PC3-TxR cell lines were described previously [Li et al., 2011] and all cell lines are described in (Table I). A GFP-ARV7 variant of DU145-TxR was constructed and designated DU145-TxRGFP-ARV7. PC3-Epi is a single cell E-cadherin/CDH1 positive PC3 clone and its M2 macrophage induced EMT derivative, PC3-EMT were described previously [Roca et al., 2013]. LNCaP-GFP and LNCaP-ARV7 were obtained from Dr. Charles Sawyers [Watson et al., 2010]. All cells were incubated at 37 °C in RPMI media (Invitrogen) supplemented with 10% fetal bovine serum (Sigma) in >95% humidity and 5% carbon dioxide [Zeng et al., 2011].

QUANTITATIVE POLYMERASE REACTION (qPCR)

Cells were disrupted with lysis buffer containing 1% 2-mercaptoethanol and shredded with a QIAshredder column (Qiagen) [Li et al., 2011]. Total RNA from lysed cells was extracted and purified using an RNeasy kit (Qiagen). The concentration and purity of RNA was assessed using a NanoDrop (ThermoScientific). Synthesis of cDNA was performed using an iScript cDNA synthesis kit (Bio-Rad). The cDNA products were diluted 20-fold with DEPC treated water before use in the Taq-man assays. Primer/probe sets were premixed (Applied Biosystems).

IMMUNOBLOTTING

Cells were lysed with protease inhibitors and centrifuged to separate the debris. Each sample was quantified by BCA analysis (Thermo) and diluted to 0.5µg/µL. 20µL was separated on a 4–15% SDS-PAGE and transferred to a nitrocellulose membrane using a TransBlot (Bio-Rad). The membranes were incubated with 1× blocking buffer (Sigma) for 1 h. The membranes were then incubated with a primary antibody at 4 °C overnight followed by a secondary (1:20,000) IRDye IgG antibody (Li-Cor Biosciences) for 1 h. All antibodies (Supplemental Table S1) were purchased from a vendor and diluted with 1× blocking buffer. The Odyssey Infrared Imaging System (Li-Cor) was used to detect protein expression while the SeeBlue ladder (Invitrogen) was used to assess molecular weight.

LUCIFERASE ASSAY

Cell lines were seeded into 24-well plates at 50,000 cells per well and transiently transfected the next day using X-tremeGene HP (Roche). The indicated ZEB1 reporter was transfected

in the same ratio as the CMV-renilla luciferase control vector in order to be about 20% of the total amount of DNA transfected [Mooney et al., 2014; Rajagopalan et al., 2014]. Data reported were normalized by dividing the firefly values by the CMV-renilla luciferase values in each well then normalized again by dividing all values by the indicated reference. The error bars indicate the standard errors which was calculated using the normalized data. The total amount of DNA for each well was always 0.5µg and so the amounts were kept consistent using pcDNA3 as the empty vector control.

RESULTS

ZEB1 EXPRESSION IN CELL LINES

The expression of various epithelial and mesenchymal cell markers was assessed in the eight prostate cancer cell lines (Table I) used in these studies. PC3-TxR and DU145-TxR came from cell lines treated with the chemotherapy paclitaxel which causes EMT [Kim et al., 2013]. Likewise, PC3-EMT was induced to a mesenchymal phenotype by incubation with M2 macrophages [Roca et al., 2013]. ZEB1 expression was used to categorize the cell lines into two groups, one that had extremely low expression of ZEB1: (PC3-Epi, LNCaP-GFP, LNCaP-ARV7) and another group with high expression: (PC3-TxR, PC3-EMT, DU145, DU145-TxR, DU145-TxR-ARV7) (Fig. 1A and B). Other markers including E-cadherin/CDH1 and OVOL1/2 supported these categories (Fig. 1C).

ZEB1 PROMOTER DISSECTION

ZEB1 expression was modulated at the promoter level in seven out of eight cell lines tested (Fig. 2). Interestingly, LNCaP-GFP and LNCaP-ARV7 had almost identical patterns to each other and very similar patterns to their AR-null counterparts. The presence of the region from ZEB1_{-65/+49} elicited a dramatically higher ZEB1 expression in seven out of eight cell lines tested. The increased expression in the constructs with ZEB1_{-65/+49} may be due to the presence of a transcriptional start site; however, it is interesting that the scale of activation is very similar across cell lines.

AR REGULATES THE DISTAL ARE IN ZEB1

To elucidate whether AR could positively regulate ZEB1 levels via distal AREs, luciferase assays were conducted. These luciferase assays were performed in the AR-null cell line, DU145, and revealed that increasing amounts of AR were able to increase activity on luciferase promoters in an R1881 dependent manner (Fig. 3). As expected, increasing amounts of ARV7 had a similar effect on luciferase activity independent of synthetic androgen, R1881. It should be noted that in both DU145 and DU145-TxR cells AR translocated to the nucleus in an R1881 dependent manner while GFP-AR/ARV7 did not require R1881 for AR translocation (immunofluorescence not shown). In order to confirm binding of AR to the proposed sequence, a mutant containing four nucleotides in the proposed ARE was developed (schematic is in Supplemental Fig. S1). Interestingly, it had no effect on ZEB1 promoter activity, possibly because the mutant was close enough to a consensus sequence that the binding kinetics were not altered.

BOTH THE DISTAL AND PROXIMAL ARE TOGETHER ARE NOT AR DEPENDENT

Inclusion of both AREs (Androgen Receptor Elements) were postulated to be synergistic [Anose and Sanders, 2011]. Inexplicably however, AR failed to further activate AR transcription on any of the promoters (Fig. 4). Additionally, mutation of the proximal ARE had either no effect or a positive effect on some promoters. In order to determine the relationship between the two AREs, cell lines were transfected with two ZEB1 constructs, pGL4-ZEB1_{-867/+50} and pGL4-ZEB1_{-740/+50}, surprisingly, removing the entire distal ARE had a positive effect on ZEB1 transcription in six out of eight cell lines (Fig. 5A); however, further addition of AR failed to increase transcription in DU145 luciferase promoter assays (Fig. 5B) on the pGL4-ZEB1_{-740/+50}. Interestingly, this figure actually confirms that both AREs synergize in AR positive LNCaP, however, it also indicates that both AREs together are inhibitory to all AR negative cell lines. Since the transcriptional start site is present in all constructs, this figure indicates that there is an inhibitory region within ZEB1_{-867/-741} that is not regulated by AR.

R1881 FAILED TO INDUCE ZEB1 EXPRESSION WITH ENDOGENOUS AR

In order to determine whether a positive effect on ZEB1 transcription would be seen in a more physiological system, the AR positive LNCaP-GFP or LNCaP-ARV7 were transiently transfected with either ZEB1_{-867/-66/+51/+291} or ZEB1_{-867/+291} luciferase promoters and incubated with various concentrations of R1881 (Fig. 6A and B). These promoters were used since they had the greatest difference in expression (41/32-fold for LNCaP-GFP and LNCaP-ARV7) compared to ZEB1_{-867/-66/+51/+367} or ZEB1_{-867/+367} (9/7.5-fold for LNCaP-GFP and LNCaP-ARV7) as shown in (Fig. 2). In this experiment, phenol-red free RPMI, supplemented with charcoal stripped FBS was used to prevent the possibility of AR activation and its nuclear translocation. Interestingly, R1881 had no effect on the luciferase promoters. Additionally, results from qPCR revealed that endogenous ZEB1 was not affected while PSA had a characteristic upregulation due to AR signaling. These results (Fig. 6C and D) coincide with a previous report indicating that R1881 failed to induce endogenous ZEB1 expression [Anose and Sanders, 2011].

DISCUSSION

It has been reported that AR is positively associated with ZEB1 expression in triple negative breast cancer cells [Graham et al., 2010]. However, AR is only expressed in the latest stages of breast cancer while it is expressed in the early stages of prostate cancer and even in normal prostate tissue where it is vital for prostate development and differentiation. Another study did demonstrate that constitutively active AR, but not full length AR caused upregulation of ZEB1 in LNCaP cells [Cottard et al., 2013]. Interestingly, the immunoblotting and qPCR results from the previous study were done for a maximum of 9 days after transient transfections by sorting out GFP positive cells. This data is actually not contradictory to the work described here since we used stably transfected cell lines for our qPCR and immunoblotting studies. Using transient transfection may produce different results since AR may be able to upregulate ZEB1 in the short-term but does not lead to a stable EMT.

Another report demonstrates that the presence of both AREs are essential to ZEB1 transcription in PC3-AR cells which have been stably transfected with full length AR [Anose and Sanders, 2011]. The authors further demonstrate that dihydrotestosterone (DHT) was able to upregulate ZEB1 on an artificial β -galactosidase reporter in LNCaP and LNCaP derivatives in a dose dependent manner. However, the authors did not demonstrate the upregulation of endogenous ZEB1 expression in these cell lines, which is consistent with our results [Anose and Sanders, 2011].

Although our data would suggest that AR does not regulate ZEB1 under physiological conditions, this may not be compulsory. Cancer is a heterogeneous cell population that can have differing DNA methylation patterns, histone marks, and transcription factor expression [Mooney et al., 2010a,b; Rajagopalan et al., 2011; Kulkarni et al., 2012]. In this way, there may be situations in which the truncated ZEB1 promoters used in this study actually mimic the in vivo situation better than the longer constructs containing both distal and proximal AREs.

In the systems used in this report the distal ARE is AR sensitive (Fig. 3) whereas the proximal ARE is not (Fig. 4). Inclusion of the proximal ARE is more strongly activating than the distal ARE (Fig. 2). In fact, the inclusion of both AREs was actually somewhat repressive in six out of eight cell lines even in the absence of AR (Fig. 5). It is most likely that there is a transcription initiation complex that binds in the vicinity of the proximal ARE (Fig. 7). This unknown complex may not include AR and is actually activated in AR positive and negative cell lines. ChIP-seq and ChIP-onChIP studies also suggest that these sites are not bound by AR in AR positive cell lines: abl, LNCaP, and VCaP cell lines [Wang et al., 2009; Massie et al., 2011]. AR itself can slightly upregulate the expression of ZEB1 however, its effect is only on the distal ARE which is normally bound by repressors in both AR negative and positive cell lines. Future work should focus on the region of the proximal ARE in order to determine the identities of actual transcription factors that regulate the ZEB1 promoter and on the distal ARE to determine repressors of ZEB1 expression.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Abbreviation

AR	androgen receptor
ARE	androgen receptor element
EMT	epithelial to mesenchymal transition
GFP	green fluorescent protein
ZEB1	zinc finger E-box-binding homeobox 1

REFERENCES

- Anose BM, Sanders MM. Androgen receptor regulates transcription of the ZEB1 transcription factor. *Int J Endocrinol*. 2011; 2011:903918. [PubMed: 22190929]
- Cottard F, Asmane I, Erdmann E, Bergerat JP, Kurtz JE, Ceraline J. Constitutively active androgen receptor variants upregulate expression of mesenchymal markers in prostate cancer cells. *PLoS One*. 2013; 8:e63466. [PubMed: 23658830]
- Graham TR, Yacoub R, Taliaferro-Smith L, Osunkoya AO, Odero-Marah VA, Liu T, Kimbro KS, Sharma D, O'Regan RM. Reciprocal regulation of ZEB1 and AR in triple negative breast cancer cells. *Breast Cancer Res Treat*. 2010; 123:139–147. [PubMed: 19921427]
- Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB, Bova GS, Luo J. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. *Cancer Res*. 2009; 69:16–22. [PubMed: 19117982]
- Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, Edwards J, Isaacs WB, Nelson PS, Bluemn E, Plymate SR, Luo J. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. *Cancer Res*. 2012; 72:3457–3462. [PubMed: 22710436]
- Hugo HJ, Pereira L, Suryadinata R, Drabsch Y, Gonda TJ, Gunasinghe NP, Pinto C, Soo ET, van Denderen B, Hill P, Ramsay RG, Sarcevic B, Newgreen DF, Thompson EW. Direct repression of MYB by ZEB1 suppresses proliferation and epithelial gene expression during epithelial-to-mesenchymal transition of breast cancer cells. *Breast Cancer Res*. 2013; 15:R113. [PubMed: 24283570]
- Kim JJ, Rajagopalan K, Hussain B, Williams BH, Kulkarni P, Mooney SM. CETN1 is a cancer testis antigen with expression in prostate and pancreatic cancers. *Biomark Res*. 2013; 1:22. [PubMed: 24252580]
- Kulkarni P, Shiraishi T, Rajagopalan K, Kim R, Mooney SM, Getzenberg RH. Cancer/testis antigens and urological malignancies. *Nat Rev Urol*. 2012; 9:386–396. [PubMed: 22710665]
- Li Y, Zeng Y, Mooney SM, Yin B, Mizokami A, Namiki M, Getzenberg RH. Resistance to paclitaxel increases the sensitivity to other microenvironmental stresses in prostate cancer cells. *J Cell Biochem*. 2011; 112:2125–2137. [PubMed: 21465536]
- Massie CE, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L, Warren A, Scott H, Madhu B, Sharma N, Bon H, Zecchini V, Smith DM, Denicola GM, Mathews N, Osborne M, Hadfield J, Macarthur S, Adryan B, Lyons SK, Brindle KM, Griffiths J, Gleave ME, Rennie PS, Neal DE, Mills IG. The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. *EMBO J*. 2011; 30:2719–2733. [PubMed: 21602788]
- Moes M, Le Behec A, Crespo I, Laurini C, Halavatyi A, Vetter G, Del Sol A, Friederich E. A novel network integrating a miRNA-203/SNAI1 feedback loop which regulates epithelial to mesenchymal transition. *PLoS One*. 2012; 7:e35440. [PubMed: 22514743]
- Mooney SM, Goel A, D'Assoro AB, Salisbury JL, Janknecht R. Pleiotropic effects of p300-mediated acetylation on p68 and p72 RNA helicase. *J Biol Chem*. 2010a; 285:30443–30452. [PubMed: 20663877]
- Mooney SM, Grande JP, Salisbury JL, Janknecht R. Sumoylation of p68 and p72 RNA helicases affects protein stability and transactivation potential. *Biochemistry*. 2010b; 49:1–10. [PubMed: 19995069]
- Mooney SM, Qiu RR, Kim JJ, Sacho EJ, Rajagopalan K, Johng D, Shiraishi T, Kulkarni P, Weninger KR. The Cancer/Testis Antigen PAGE4, a Regulator of c-Jun Transactivation, is Phosphorylated by Homeodomain-interacting Protein Kinase 1, a Component of the Stress-response Pathway. *Biochemistry*. 2014; 53(10):1670–1679. [PubMed: 24559171]
- Ni L, Llewellyn R, Kesler CT, Kelley JB, Spencer A, Snow CJ, Shank L, Paschal BM. Androgen induces a switch from cytoplasmic retention to nuclear import of the androgen receptor. *Mol Cell Biol*. 2013; 33:4766–4778. [PubMed: 24100013]
- Pienta KJ, Bradley D. Mechanisms underlying the development of androgen-independent prostate cancer. *Clin Cancer Res*. 2006; 12:1665–1671. [PubMed: 16551847]

- Rajagopalan K, Mooney SM, Parekh N, Getzenberg RH, Kulkarni P. A majority of the cancer/testis antigens are intrinsically disordered proteins. *J Cell Biochem.* 2011; 112:3256–3267. [PubMed: 21748782]
- Rajagopalan K, Qiu R, Mooney SM, Rao S, Shiraishi T, Sacho E, Huang H, Shapiro E, Weninger KR, Kulkarni P. The Stress-response protein prostate-associated gene 4, interacts with c-Jun and potentiates its transactivation. *Biochim Biophys Acta.* 2014; 1842:154–163. [PubMed: 24263171]
- Renthal NE, Chen CC, Williams KC, Gerard RD, Prange-Kiel J, Mendelson CR. MiR-200 family and targets, ZEB1 and ZEB2, modulate uterine quiescence and contractility during pregnancy and labor. *Proc Natl Acad Sci USA.* 2010; 107:20828–20833. [PubMed: 21079000]
- Roca H, Hernandez J, Weidner S, McEachin RC, Fuller D, Sud S, Schumann T, Wilkinson JE, Zaslavsky A, Li H, Maher CA, Daignault-Newton S, Healy PN, Pienta KJ. Transcription factors OVOL1 and OVOL2 induce the mesenchymal to epithelial transition in human cancer. *PLoS One.* 2013; 8:e76773. [PubMed: 24124593]
- Salnikov AV, Liu L, Platen M, Gladkich J, Salnikova O, Ryschich E, Mattern J, Moldenhauer G, Werner J, Schemmer P, Buchler MW, Herr I. Hypoxia induces EMT in low and highly aggressive pancreatic tumor cells but only cells with cancer stem cell characteristics acquire pronounced migratory potential. *PLoS One.* 2012; 7:e46391. [PubMed: 23050024]
- Sun Y, Wang BE, Leong KG, Yue P, Li L, Jhunjhunwala S, Chen D, Seo K, Modrusan Z, Gao WQ, Settleman J, Johnson L. Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy. *Cancer Res.* 2012; 72:527–536. [PubMed: 22108827]
- Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhi R, Wang H, Lupien M, Wu T, Regan MM, Meyer CA, Carroll JS, Manrai AK, Janne OA, Balk SP, Mehra R, Han B, Chinnaiyan AM, Rubin MA, True L, Fiorentino M, Fiore C, Loda M, Kantoff PW, Liu XS, Brown M. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. *Cell.* 2009; 138:245–256. [PubMed: 19632176]
- Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K, Sawyers CL. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. *Proc Natl Acad Sci USA.* 2010; 107:16759–16765. [PubMed: 20823238]
- Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D, zur Hausen, Brunton A, Morton VG, Sansom J, Schuler O, Stemmler J, Herzberger MP, Hopt C, Keck U, Brabletz T, Brabletz S. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. *Nat Cell Biol.* 2009; 11:1487–1495. [PubMed: 19935649]
- Yang KR, Mooney SM, Zarif JC, Coffey DS, Taichman RS, Pienta KJ. Niche inheritance: a cooperative pathway to enhance cancer cell fitness through ecosystem engineering. *J Cell Biochem.* 2014; 115:1478–1485. [PubMed: 24700698]
- Zeng Y, He Y, Yang F, Mooney SM, Getzenberg RH, Orban J, Kulkarni P. The cancer/testis antigen prostate-associated gene 4 (PAGE4) is a highly intrinsically disordered protein. *J Biol Chem.* 2011; 286:13985–13994. [PubMed: 21357425]

Fig. 1. Various cell lines were assayed for mesenchymal and epithelial markers. (A) Immunoblotting for ZEB1, E-cadherin, AR, and β -Actin. (B) qPCR for the epithelial markers OVOL1/2, ESRP1, and E-cadherin with PC3-TxR normalized to 1. (C) qPCR for the mesenchymal ZEB1 and ZEB2 with PC3-Epi normalized to 1.

Fig. 2.

The region around the proximal ARE regulates the ZEB1 promoter in the absence of AR. Each well of a 24 plate was transfected with 100 ng of the specified ZEB1 promoter, 100 ng CMV-renilla, and 400 ng pCDNA3. Experiments were done a minimum of three times in quadruplicate and normalized to pGL4-ZEB1_{-866/-67}.

Fig. 3.

The region around the distal ARE is regulated by AR. A schematic is shown on the left, which depicts the distal ARE promoter nucleotides underlined and the mutated nucleotides as lower case letters. The luciferase assays were conducted with various promoter lengths in DU145 cells. Firefly luciferase activity was divide by CMV-renilla activity and the resulting ratio was normalized to 1 in each graph for no AR.

Fig. 4.

The region around the distal but not the proximal ARE is regulated by AR. A schematic is shown on the left, which depicts the proximal ARE promoter nucleotides underlined and the mutated nucleotides as lower case letters. The luciferase assays were conducted with various promoter lengths in DU145 cells. Firefly luciferase activity was divide by CMV-renilla activity and the resulting ratio was normalized to 1 in each graph for no AR.

Fig. 5.

The region around the distal ARE is repressive in AR-negative cell lines. (A) Each well of a 24 plate was transfected with 100 ng of the either pGL4-ZEB1_{-866/+50} or pGL4-ZEB1_{-740/+50} promoter, 100 ng CMV-renilla and 400 ng pcDNA3. Experiments were done a minimum of three times in quadruplicate and normalized to pGL4-ZEB1_{-866/+50}. (B) DU145 cells were transfected with pGL4-ZEB1_{-740/+50} with various amounts of AR. The case with no AR was normalized to 1. Mutations were done to the 3' ARE as shown in Figure 4.

Fig. 6.

Endogenous AR or stably expressed ARV7 had little effect on ZEB1 expression. (A) Either pGL4-ZEB1_{-866/-66/+51/+291} or pGL4-ZEB1_{-866/+291} were transfected into the indicated LNCaP cell line with various amounts of R1881. Normalization was done to the no R1881 control. (B) The indicated LNCaP cells were grown for 36 h in media supplemented with various amounts of R1881. Triplicate qPCR for ZEB1/PSA is shown normalized to β -Actin. Experiments in (A, B) were done in charcoal stripped FBS with colorless RPMI.

Fig. 7. Models of AR-independent and -dependent ZEB1 modulation. AR binds in the vicinity of the proposed distal ARE as a dimer whereas in our model, the proximal ARE is not bound by AR at all instead some unknown factors which enhance ZEB1 promoter activity to a larger degree than AR.

TABLE I

Description of the Cell Lines Used

Cell line	Description
PC3-EPI	CDH1+ subpopulation of PC3
PC3-EMT	M2 induced mesenchymal clone of PC3-Epi
PC3-TxR	PC3 cells treated with long term Paclitaxel
DU145	Derived from brain metastasis
DU145-TxR	DU145 cells treated with long term Paclitaxel
DU145-TxR-GFP-ARV7	DU145-TxR stable transfected with GFP-ARV7
LNCaP-GFP	LNCaP stably transfected with GFP
LNCaP-ARV7	LNCaP stable transfected with untagged ARV7